morphology using the strict criteria and IUI success rates (measured by clinical pregnancies per cycle of IUI) published through April 2016. Studies were eligible for inclusion if they assessed IUI pregnancy success rate for percent sperm morphology >4% and 4% or percent sperm morphology !1% and <1%. Estimates were pooled using random-effects meta-analysis. Differences by study-level characteristics were estimated using meta-regression.
INTRODUCTION AND OBJECTIVES: The role of redo varicocelectomy in infertile males with recurrent or persistent varicocele is controversial in the era of assisted reproductive technology (ART). The aim of the study was to compare sperm parameters, pregnancy and miscarriage rates between the men with recurrent or persistent varicocele who underwent redo microsurgical subinguinal varicocelectomy or had observation only.
METHODS: The study included 217 infertile men with recurrent or persistent varicocele. The patients were divided into two groups: 120 men underwent redo microsurgical subinguinal varicocele repair, and 97 had observation only, as the control group. All patients had clinical varicoceles, and recurrences were confirmed with color Doppler ultrasound. Indications for redo varicocelectomy were no improvement in semen parameters and not achieving pregnancy after at least 6 months of initial varicocelectomy. Difference in total motile sperm count (TMSC), serum follicle stimulating hormone (FSH) and total testosterone levels from the beginning to the end of the study, pregnancy (spontaneous or with the use of ART) and miscarriage rates were compared between the two groups.
RESULTS: Baseline mean patient and female partners ages, recurrent varicocele sites, TMSC, serum FSH and total testosterone levels, time to recurrence and follow-up period did not significantly differ between the two groups. The mean TMSC increased from 20.93AE2.87 to 45.54AE6.28 million in the microsurgical redo varicocelectomy group, and decreased from 16.62AE2.75 to 15.6AE2.81 million in the control group, revealing significant difference between the two groups (p¼0.000). Increase in total testosterone was significantly higher in the microsurgical redo varicocelectomy group (+1.36AE0.32 ng/ml) than in the control group (-0.23AE0.1 ng/ml) (p¼0.000). Of the couples, 63 (52.5%) achieved to pregnancy in the redo microsurgical varicocelectomy group, and 38 (39.2%) had pregnancy in the control group (p<0.05). Spontaneous pregnancy rate was significantly higher in the microsurgical varicocelectomy group (39.7%) than in the control group (15.8%) (p<0.01). Use of ART to achieve pregnancy was significantly lower in the microsurgical varicocelectomy group (60.3%) than in the control group (84.2%) (p<0.01).
CONCLUSIONS: Microsurgical subinguinal redo varicocelectomy improves postoperative semen parameters, serum total testosterone level and spontaneous pregnancy rates, compared to the controls. It also decreases need for use and level of ART. METHODS: Single centre study over 6 years of 25 adult patients of primary infertility with NOA, SO (< 5 million/ml), VA (< 1 milion/ ml) with clinical varicocele and testicular size >10cc, semen volume >1.5 ml, pH >7.2 and normal FSH, testosterone levels and normal female evaluation. Patients were operated by loupe guided microsurgical subinguinal artery, lymphatic sparing varicocelectomy followed by needle aspiration biopsy (NAB) of bilateral testes. Semen analysis was done at 3, 6 months. Response was evaluated by improvement in sperm counts, progressive motility and pregnancy outcome.
Source of
RESULTS: Mean age and mean duration of infertility were 30.64 years, 4.36 years. 18 patients had grade 2 varicocele, 4 had grade 1, 3 had grade 3 with mean grade of 1.96. Average testicular size was 19.16 cc. Mean counts improved from 1.052 to 8.456 (million/ml) (p<0.0001). Mean progressive motility improved from 15.76% to 24.4% (p<0.001). Twenty-one (84%) patients responded and four patients (16%) did not respond. Between two groups age, duration and grade were not significantly different. Amongst NOA, VA, SO groups; age, duration, grade, testicular size were not significantly different. 5 patients had pregnancy (2 spontaneous, 3 IUI). Mean time was 15 months (spontaneous), 4.5 months (IUI). They had significant improvement in motility (p 0.003). Grade was significantly different in pregnant (2.4) and non-pregnant (1.85) groups (p 0.048). On NAB 4 had hypospermatogenesis, 1 had late MA. In follow up no-one had recurrence, 1 patient had unilateral hydrocele. Limitations were small sample size and nonrandomisation.
CONCLUSIONS: Significant improvement in sperm counts and motility occurred after varicocelectomy in general (NOA, VA, SO). Age >33 years, duration >7.75 years, abnormal testicular histology were risk factors for non-responsiveness. Hypospermatogenesis was relatively better and early MA was worst for pregnancy outcome.
INTRODUCTION AND OBJECTIVES: Premature Ejaculation
(PE) is associated with rapid ejaculation, inability to delay ejaculation and distress. There are no approved pharmacological treatments in US.
The objective was to test the efficacy and safety of IX-01, an orally administered selective oxytocin receptor (OTR) antagonist with potential to treat PE.
METHODS: A double-blind, placebo-controlled trial (NCT02232425) was performed in US and Australia. Eligibility criteria included lifelong PE, !4 intercourse attempts during a 4 week run-in, with intravaginal ejaculatory latency time (IELT) 1 minute measured by stopwatch on !75% occasions and none > 2 minutes. Men were randomized (2:1) to receive IX-01 or placebo taken 1-6 hours before intercourse during 8 weeks treatment. The starting dose was 400 mg and could be increased to 800 mg or equivalent placebo. Efficacy was assessed by IELT, Clinical Global Impression of Change (CGIC), and Premature Ejaculation Profile (PEP). Safety assessments included adverse events (AEs), vital signs, laboratory tests, electrocardiograms, and depression scales.
RESULTS: Eighty-six men (mean age 43 years) received !1 dose of study drug. Men took a mean of 14.6 (range 1-59) and 13.0 (range 1-51) doses of IX-01 and placebo respectively. Fifty (89.3%) men took the maximum 800 mg dose of IX-01 at least once during the study. The main efficacy results are depicted in Table 1 . IX-01 showed clinically and statistically significant improvements in IELT and patient reported outcomes compared to placebo. A summary of the AE 0 s is presented in Table 2 . The AE profile of IX-01 was similar to placebo. No other safety signals were detected.
CONCLUSIONS: This is the first study to demonstrate the efficacy of an OTR antagonist to treat PE. IX-01 was well tolerated and prolonged IELT, and improved ejaculation control and diminished distress in men with lifelong PE. is the most common form of sexual dysfunction in men yet few safe and effective therapies exist. A variety of local anesthetics have been studied, but lack of efficacy has restricted widespread use. We performed a randomized, double-blind controlled trial to evaluate the use of a novel topical 4% benzocaine wipe for management of PE.
Source of
METHODS: We enrolled men aged ! 18 years in a heterosexual, monogamous relationship with PE as defined by self-reported poor control over ejaculation, personal distress related to ejaculation, and average intravaginal ejaculatory latency time (IELT) 2 minutes on stopwatch measurement. Subjects were randomized in a 2:1 fashion to treatment with benzocaine wipes or placebo. One month after randomization, men in the placebo group were crossed over to the treatment group. Primary outcome was change in IELT at two months. Secondary outcomes included change in questionnaire assessments e1344 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 
